In vitro determination of patient-specific variation challenges the universal RBE gold standard for proton radiation therapy

  • Clin Transl Radiat Oncol. 2025 Sep 15:56:101046. doi: 10.1016/j.ctro.2025.101046.
Anna Kirstein  1 ,  Dan Ionascu  2 ,  Michael A S Lamba  2 ,  Bianca M Ruffolo  1 ,  Katherine J Crail  1 ,  Anthony E Mascia  1  2 ,  Mathieu G Sertorio  2 ,  Benjamin H Hinrichs  3 ,  Chad Zender  4 ,  Maria A Lehn  5 ,  Trisha M Wise-Draper  5 ,  John P Perentesis  1 ,  Yi Zheng  1 ,  Susanne I Wells  1
Affiliations
  • 1. Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
  • 2. Department of Radiation Oncology, College of Medicine, University of Cincinnati, Cincinnati OH 45219, USA.
  • 3. Department of Pathology & Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45219, USA.
  • 4. Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati, Cincinnati, OH 45219, USA.
  • 5. Department of Internal Medicine, Division of Hematology/Oncology, University of Cincinnati, College of Medicine, Cincinnati, OH 45267, USA.
PMID: 41049395 DOI: 10.1016/j.ctro.2025.101046
Keywords
Head and Neck Squamous Cell Carcinoma (HNSCC); Proton therapy; Radiation; Relative biological effectiveness (RBE); X-ray radiation.
Products